PL367630A1 - Zastosowanie acetylo-L-karnityny w połączeniu z biotyną do leczenia pacjentów cierpiących na cukrzycę insulino-niezależną typu 2 - Google Patents

Zastosowanie acetylo-L-karnityny w połączeniu z biotyną do leczenia pacjentów cierpiących na cukrzycę insulino-niezależną typu 2

Info

Publication number
PL367630A1
PL367630A1 PL02367630A PL36763002A PL367630A1 PL 367630 A1 PL367630 A1 PL 367630A1 PL 02367630 A PL02367630 A PL 02367630A PL 36763002 A PL36763002 A PL 36763002A PL 367630 A1 PL367630 A1 PL 367630A1
Authority
PL
Poland
Prior art keywords
carnitine
biotin
insulin
acetyl
patients
Prior art date
Application number
PL02367630A
Other languages
English (en)
Other versions
PL207522B1 (pl
Inventor
Menotti Calvani
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of PL367630A1 publication Critical patent/PL367630A1/pl
Publication of PL207522B1 publication Critical patent/PL207522B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL367630A 2001-05-29 2002-05-24 Zastosowanie acetylo-L-karnityny w połączeniu z biotyną PL207522B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001RM000294A ITRM20010294A1 (it) 2001-05-29 2001-05-29 Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re
PCT/IT2002/000338 WO2002096410A1 (en) 2001-05-29 2002-05-24 Use of the acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus

Publications (2)

Publication Number Publication Date
PL367630A1 true PL367630A1 (pl) 2005-03-07
PL207522B1 PL207522B1 (pl) 2010-12-31

Family

ID=11455558

Family Applications (1)

Application Number Title Priority Date Filing Date
PL367630A PL207522B1 (pl) 2001-05-29 2002-05-24 Zastosowanie acetylo-L-karnityny w połączeniu z biotyną

Country Status (18)

Country Link
US (2) US20040142879A1 (pl)
EP (1) EP1399142B1 (pl)
JP (1) JP4381685B2 (pl)
KR (1) KR20040010666A (pl)
AT (1) ATE333274T1 (pl)
CA (1) CA2448244C (pl)
CY (1) CY1105403T1 (pl)
CZ (1) CZ297743B6 (pl)
DE (1) DE60213237T2 (pl)
DK (1) DK1399142T3 (pl)
ES (1) ES2268053T3 (pl)
HU (1) HUP0400060A2 (pl)
IT (1) ITRM20010294A1 (pl)
MX (1) MXPA03010921A (pl)
PL (1) PL207522B1 (pl)
PT (1) PT1399142E (pl)
SK (1) SK287832B6 (pl)
WO (1) WO2002096410A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833977B2 (en) * 2000-12-15 2010-11-16 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of L-Carnitine as stabilizing agent of proteins
ITRM20040327A1 (it) * 2004-07-01 2004-10-01 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina per la preparazione di un medicamento per il trattamento del dolore neuropatico in pazienti diabetici.
US8569366B2 (en) * 2005-04-26 2013-10-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Acetyl L-carnitine for prevention of painful peripheral neuropathy in patients with type 2 diabetes
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
EA018442B1 (ru) * 2007-03-21 2013-08-30 Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. Применение l-карнитина для лечения гипертензии, для снижения систолического или пульсового давления крови у субъектов с предиабетом
GB201304112D0 (en) * 2013-03-07 2013-04-24 Univ Nottingham Modulation of energy expenditure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
US6020139A (en) * 1995-04-25 2000-02-01 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
US5789401A (en) * 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes

Also Published As

Publication number Publication date
KR20040010666A (ko) 2004-01-31
US20040142879A1 (en) 2004-07-22
ES2268053T3 (es) 2007-03-16
HUP0400060A2 (hu) 2004-04-28
EP1399142B1 (en) 2006-07-19
CA2448244C (en) 2010-11-02
WO2002096410A1 (en) 2002-12-05
EP1399142A1 (en) 2004-03-24
PL207522B1 (pl) 2010-12-31
US20080269307A1 (en) 2008-10-30
DK1399142T3 (da) 2006-10-30
CZ20033221A3 (cs) 2004-06-16
ATE333274T1 (de) 2006-08-15
JP2004532866A (ja) 2004-10-28
JP4381685B2 (ja) 2009-12-09
PT1399142E (pt) 2006-10-31
MXPA03010921A (es) 2004-02-27
ITRM20010294A0 (it) 2001-05-29
CZ297743B6 (cs) 2007-03-21
ITRM20010294A1 (it) 2002-11-29
DE60213237D1 (de) 2006-08-31
DE60213237T2 (de) 2007-08-02
SK287832B6 (sk) 2011-11-04
US8053472B2 (en) 2011-11-08
CY1105403T1 (el) 2010-04-28
CA2448244A1 (en) 2002-12-05
SK15852003A3 (sk) 2004-04-06

Similar Documents

Publication Publication Date Title
TW200505881A (en) Tri(cyclo) substituted amide compounds
AP2000001929A0 (en) Substituted indolealkanoic acids.
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
CA2407100A1 (en) 1-aroyl-piperidinyl benzamidines
GB0223038D0 (en) Therapeutic compounds
AU2003281978A1 (en) 2,5-diketopiperazines for the treatment of obesity
MXPA04003666A (es) Uso de flibanserina para tratamiento de trastornos sexuales.
MY121517A (en) Anticonvulsant derivatives useful in reducing blood glucose levels
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
AU2000276362A1 (en) Composition for the treatment of diabetes
NZ516290A (en) Substituted phenoxyacetic acids
MY134167A (en) Biphenylcarboxamides useful as lipid lowering agents
GB2431346C (en) A combination composition comprising paracetamol and ibuprofen
AU2003252182A8 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
MXPA03010921A (es) Uso de acetil l-carnitina en asociacion con biotina para tratamiento der pacientes con diabetes mellitus resistente a insulina tipo 2.
IL162853A0 (en) The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
AU2002314518A1 (en) Use of the acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
GB0212790D0 (en) Medicament for the treatment of diabetes
GB0128071D0 (en) Medicament
ITMI20030827A1 (it) Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
CA2304899A1 (en) New use of selective serotonin reuptake inhibitors for treatment of human patients with chest pain of non-cardiac origin or with gastro-esophageal reflux disease
BR0211522A (pt) Tratamento de dor crÈnica com 3-arilóxi-3-fenilpropanaminas
AU2001262786A1 (en) Use of l-2-oxothiazolidine-4-carboxylic acid for the treatment of type 2 diabetes

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20130524